The action of sumatriptan, a selective 5-HT) like receptor agonist that is effective for the acute treat ment of migraine, was compared on pial vessel diameter following perivascular or intravenous administration to anaesthetised cats. Sumatriptan (0.01-10 /J-M), when mi croinjected perivascularly, caused a decrease in pial ar tery diameter (maximum change of -19 ± 9%; mean ± SD) but had no effect on the diameter of pial veins. Suma triptan (l /J-M)-induced pial artery vasoconstriction was unaffected by coadministration of ketanserin (l /J-M) or ondansetron (l /J-M) but was significantly (p < 0.01) at tenuated by methiothepin (l/J-M). Intravenous infusion of a clinically effective dose of sumatriptan (64 /J-g/kg/l0 min) caused selective carotid vasoconstriction (22 ± 6%
Sumatriptan (GR43175) is a novel, highly selec tive agonist for the 5-HT1-like receptor, which me diates vasoconstriction of certain blood vessels (Humphrey et aI., 1988) . This 5-HT1 receptor sub type was first identified in dog isolated saphenous vein but appears to be largely restricted to intracra nial blood vessels (Humphrey et aI., 1988 (Humphrey et aI., , 1990b . Thus, it has been shown that sumatriptan causes contraction of isolated large cerebral arteries from dog, primate, and humans (Connor et aI., 1989; Par sons et aI., 1989) and human isolated dural arteries (Humphrey et aI., 1990b) via activation of 5-HTJlike receptors but has little or no effect on tone in most peripheral isolated vascular preparations (Humphrey et aI., 1988) . Similarly, in vivo, suma triptan selectively constricts the carotid vascular bed in anaesthetised dogs (Feniuk et aI., 1989) and cats (Perren et aI., 1989) . This selective action of sumatriptan for the cranial vasculature reflects the increase in carotid vascular resistance with little or no change in blood pressure or heart rate) and no change in pial artery diameter, although sumatriptan (l /J-M) admin istered perivascularly in these animals before and after the infusion caused pial artery vasoconstriction. These results demonstrate that perivascularly administered sumatriptan causes pial artery vasoconstriction via acti vation of 5-HTclike receptors. However, intravenously administered sumatriptan does not cause pial artery va soconstriction, which suggests that sumatriptan does not readily penetrate the cerebrovascular intima. Key Words: Sumatriptan-5-HT) receptor-Migraine-Pial vessel di ameter-Cats. distribution of vascular 5-HT receptors such that 5-HT J-like receptors that mediate contraction ap pear to be confined largely to the cranial circulation while, in contrast, 5-HT2 receptors mediate con traction in most of the peripheral vasculature (Hum phrey et aI., 1990b) .
This understanding has led to the evaluation of sumatriptan in the acute treatment of migraine (Cady et aI., 1991; Ensink, 1991; Ferrari et aI., 1991; Patten, 1991) . It has been proposed that during a migraine headache, intracranial blood vessels in the dura and large arteries supplying the brain are dis tended, inflamed, and pain sensitive (Moskowitz et aI., 1989) . Therefore, the ability of sumatriptan to constrict these blood vessels selectively may ac count for its antimigraine activity in humans (Hum phrey, 1991) . However, despite its ability to con tract isolated large cerebral arteries, sumatriptan does not appear to modify global CBF in animals (Perren et aI., 1989) or humans (Friberg et aI., 1991) . The present study was designed to investi gate further the vasoconstrictor effect of sumatrip tan in the cerebral circulation. The influence of sumatriptan on the diameter of pial arteries and veins following perivascular microapplication has been studied in anaesthetised cats. Furthermore, the pial artery diameter has been measured during intravenous administration of sumatriptan in order to provide an assessment of its ability to penetrate the cerebrovascular intima. A preliminary account of some of these findings has been presented in brief (Humphrey et ai., 1991) .
METHODS

General
Cats of either sex (2.5-3.5 kg; n = 14) were anaesthe tised with chloralose suspension (80 mg kg-I i.p.) and pentobarbitone (10 mg kg-I i.p.). The left femoral artery was cannulated for measurement of blood pressure; heart rate was derived from the pulse pressure signal. A can nula was inserted into the left femoral vein for intrave nous administration of drugs. In some animals, a Doppler flow probe (1.6 mm diameter, University of Iowa) was placed around the left common carotid artery; blood flow was measured via a directional pulsed Doppler flowmeter (University of Iowa). A cannula was inserted into the trachea and the animal was artificially respired (Palmer ventilation pump) with room air at a rate of 20 strokes min -I. The acid-base status in the arterial blood was regularly checked throughout each experiment by blood gas analysis (Radiometer ABL30). By adjusting the stroke volume (approximately 13 ml kg-I) or administra tion of sodium bicarbonate solution (1 M, 1 ml kg -I), pH, PaCOz, and PaOz were maintained within normal physi ological limits. Mean values for the animals used were pH = 7.36 ± 0.03, PaCOz = 30.5 ± 2.2, PaOz = 96.2 ± 6.1, n = 14. Cats were placed in a stereotaxic frame (David Kopt) and a craniotomy (about 2.0 x 1.5 cm) was per formed above the left parietal cortex using a saline-cooled dental drill. The craniotomy was covered with a layer (1-2 cm) of warmed (37°C) liquid paraffin and the dura was carefully excised to reveal the underlying pial arter ies and veins.
Measurement of pial vessel diameter
The diameter of pial arteries and veins on the surface of the parietal cortex was measured using a video micro scaler (IV-550, FOR-A) attached via a colour camera (Sony) to a binocular microscope (Meiji Labax Co. Ltd.). The image was continually displayed on a video monitor (JVC). This system allowed the vessel diameter to be measured with an error of <5% for vessels 80-240 !-Lm diameter.
Perivascular administration of substances
Artificial CSF or drugs (dissolved in artificial CSF) were administered directly to pial arteries or veins by perivascular injection. These were performed using glass micropipettes (outer tip diameter of 8-10 !-Lm) positioned into the perivascular space by use of a micromanipulator (Wahl et aI., 1989) . Injections were made using a Leitz (520144) injection device: approximately 2 !-LI was slowly infused over 30 s. The diameter of the vessel under study was continually monitored before and up to 5 min after injection; the vessel diameter returned to resting levels within this time. The interval between injections was at least 5 min. At the beginning of each experiment, normal vessel reactivity was checked by confirming that vessels dilated to perivascular injection of 10 mM K + in CSF;
this caused dilations of about 25-35%. Responses were expressed as the percentage change of the preinjection diameter. Antagonist effects were studied by coadminis tration of agonist and antagonist in the same micropipette after having first determined the response to the agonist and then the antagonist alone.
Intravenous administration of substances
In four cats, saline (0.9%) was infused (0.5 ml min-I) for 10 min using a Precidor infusion pump (Infors AG, Basel, Switzerland) via the cannula in the left femoral vein. At least 30 min later, sumatriptan (6.4 !-Lg kg-I min -I dissolved in saline) was infused intravenously for 10 min. Blood pressure, heart rate, common carotid blood flow, common carotid vascular resistance (mean blood pressure divided by carotid blood flow), and pial artery diameter were measured before and up to 30 min after the start of the infusion. Absolute values of common carotid blood flow were calculated from the Doppler equation V
Doppler shift frequency, C = velocity of sound in blood, Fo = transmitter frequency, and A = angle between the sound beam and blood velocity vector. In these same animals, the response to sumatriptan (1 !-LM), injected perivascularly to the pial artery measured for the infu sion, was determined at the beginning and end of the experiment.
Drugs and solutions
Artificial CSF was freshly prepared for each experi ment and had the following composition (mmol L -I): Na +,159.5: K +,2.5; Ca z +, 1.5; Cl-, 150.5; and HC03 -, 14.5 (Wahl et aI., 1989) . When bubbled with 5% COz in O z , this gave a pH of 7.21-7.23. Drug solutions were pre pared in artificial CSF immediately before injection. Sumatriptan was initially dissolved in artificial CSF; me thiothepin, ondansetron, and angiotensin II were initially dissolved in distilled water, and ketanserin was initially dissolved in 0.1 M tartaric acid. Dilutions were made in artificial CSF. At the dilutions used for perivascular in jection, none of the test substances altered the CSF pH.
Angiotensin II was from Nova Biochem Ltd., (Notting ham, U.K.) (±)ketanserin tartrate was from RBI (Natick, MA, U.S.A.), and methiothepin maleate was from Roche (Basel, Switzerland); sumatriptan succinate (GR43l75C) and ondansetron dihydrochloride monohydrate (GR38032F) were synthesised in the Chemical Research Department, Glaxo, Ware, U.K. The dose of sumatriptan in the infusion study refers to the base weight.
Statistical analysis
Values shown are means ± SD. Comparisons between treatments were made using Student's t test for paired or unpaired samples as appropriate.
RESULTS
Resting mean blood pressure and heart rate of cats used in this study were 110 ± 14 mm Hg and 165 ± 21 beats min -1, respectively (n = 14). These parameters were not modified by perivascular in jection of any of the agents used in this study.
Perivascular injection of sumatriptan
Perivascular injection of artificial CSF to pial ar teries had little or no effect on vessel diameter. In contrast, perivascular injection of sumatriptan (0.0 1-10 J.LM) caused a concentration-related de crease in pial artery diameter (Table 1) with a max imum effect of -19 ± 9% at 1 J.LM (preinjection pial artery diameter of 174 ± 38 J.Lm; n = 15 from six cats). Small (80-120 J.Lm) and large (120-240 J.Lm) pial arteries were constricted similarly. This effect of sumatriptan was immediate in onset and the ves sel diameter returned to preinjection levels within 2-5 min. Sumatriptan (1 and 10 J.LM perivascularly) caused no change in diameter of pial veins (Table  1) . However, in these experiments, pial veins were constricted by perivascular administration of an giotensin II (0. 1 J.LM; -16 ± 5% change in diameter, n = 8 from three animals), demonstrating that while these vessels did not respond to sumatriptan, they were able to respond to another vasoconstric tor agent.
Effect of antagonists
Ketanserin (1 J.LM), ondansetron (1 J.LM), or me thiothepin (1 J.LM) alone had no effect on pial artery diameter when injected perivascularly. Further more, ketanserin (1 J.LM) or ondansetron (1 J.LM) did not modify the decrease in pial artery diameter pro duced by sumatriptan. However, in the presence of methiothepin (1 J.LM), the vasoconstrictor effect of sumatriptan was significantly (p < 0.0 1; paired Stu dent's t test) attenuated (Fig. 1 ). This concentration of methiothepin had no effect on the decrease in pial artery diameter produced by a submaximal concen tration of angiotensin II (10 nM; -21. 6 ± 3.5 and -24.8 ± 3.6% in the absence and presence, respec tively, of methiothepin, 1 J.LM, n = 5 in two ani mals).
Effect of sumatriptan following intravenous administration
Resting mean blood pressure, heart rate, carotid blood flow, and pial artery diameter in these ani mals prior to saline infusion was 129 ± 18 mm Hg, J Cereb Blood Flow Metab, Vol. 12, No.3, 1992 198 ± 19 beats min -1,2 6 ± 10 ml min -I , and 165 ± 51 J.Lm, respectively (n = 4) (Fig. 2) . Administration of saline vehicle (0.5 ml min -I ) as a 10 min intra venous infusion had no effect on any of these pa rameters. Sumatriptan infusion (6.4 J.Lg kg-I min-I i. v. for 10 min) caused an immediate decrease in carotid blood flow and increase in carotid vascular resistance; the maximum change, measured 15 min after commencing the infusion, was -20 ± 14 and + 22 ± 6%, respectively (n = 4). This dose of suma triptan had little effect on blood pressure or heart rate, causing only a small, short-lasting, and statis tically nonsignificant (p > 0.05 compared to the pre infusion value; paired Student's t test) increase in both parameters. Sumatriptan infusion caused no change in pial artery diameter (Fig. 2) , despite the fact that perivascular administration of sumatriptan to these same pial arteries before and after the in fusion caused vasoconstriction (-18 ± 5 and -16 ± 6%, respectively, n = 8 from four animals). 
DISCUSSION
The aim of this study was to investigate the effect of sumatriptan, a selective 5-HT I-like receptor ag onist (Humphrey et al., 1988 ) on pial vessel diame ter in vivo. This agent appears to have a selective vasoconstrictor effect in the cranial circulation (see the introduction). Sumatriptan constricted pial ar teries following perivascular microapplication in anaesthetised cats. Interestingly, the concentra tions required to elicit this effect (0.1-10 flM) were identical to those that cause contraction of isolated large cerebral arteries Parsons et al., 1989) . The vasoconstrictor action of suma triptan on pial arteries in vivo was not modified by ketanserin or ondansetron. These are potent, selec tive antagonists at 5-HT2 and 5-HT3 receptors, re spectively, and the concentration used (1 flM) was at least 100-fold higher than their respective pA2 values for these receptor subtypes (Van Neuten et al., 1981; Butler et al., 1988) . In contrast, sumatrip tan-induced pial artery vasoconstriction was signif icantly antagonised by methiothepin. This blockade was specific since the vasoconstrictor effect of an giotensin II was unaffected by methiothepin. Al though having blocking activity at several 5-HT re ceptor subtypes, including 5-HT2, 5-HTJA' 5-HT I B' and 5-HT 1D receptors, methiothepin is also a rela tively potent 5-HT I -like receptor antagonist (Brad ley et al., 1986; Humphrey et al., 1988) . Together, these results suggest that perivascular injection of sumatriptan causes pial artery vasoconstriction in vivo via the same receptor, namely 5-HTclike, as previously identified in isolated large intracranial blood vessels . These 5-HTI- like receptors are presumably located on the cere brovascular smooth muscle.
In the present study, the effects of perivascularly injected sumatriptan were consistently vasocon strictor, even in the smallest pial arteries examined (80-90 flm diameter). No vasodilator responses were observed in any experiments. These findings are somewhat different from the effects of perivas cularly applied 5-HT in anaesthetised cats, where responses were reported to be dependent on the initial pial artery calibre: larger arteries tended to constrict but the more consistent response, partic ularly in smaller pial arteries, was dilation in re sponse to 5-HT (Harper and Mackenzie, 1977 ). An explanation for this difference, the basis of which we have already proposed, is that two 5-HT sub types are present in pial arteries: 5-HTJ-like recep tors mediate vasoconstriction and a different 5-HT I-like receptor subtype, not stimulated by sumatriptan, mediates vasodilation (Humphrey et al., 1990a) . Further investigation of this possibility specifically in pial arteries would require the study of compounds with selectivity for the various 5-HT receptor subtypes. Preliminary data suggest that the receptor that mediates 5-HT -induced dilation of pial arteries in rats (Pryke et al., 1989 ) is similar to the 5-HT receptor that causes endothelium-dependent relaxation of rabbit isolated jugular vein; this recep tor is described as 5-HT clike but is clearly different from the 5-HTclike receptor mediating vasocon striction (Martin et al., 1987) .
Previous studies have shown that sumatriptan contracts isolated large cerebral arteries, such as the basilar and middle cerebral arteries, from many species including humans (Parsons et al., 1989) and cat (Connor, unpublished observations) via 5-HTc like receptor activation. However, these are con ducting arteries and thus would not be expected to be major determinants of CBF. The present study demonstrates that the smaller pial arteries located on the brain surface are also constricted by suma triptan; these vessels can have an influence on CBF (Kobayashi et al., 1985) . However, a previous study has reported that sumatriptan does not mod ify CBF following intravenous administration to anaesthetised cats, even at relatively high doses (up to 1 mg/kg i.v.) . Furthermore, a clinically relevant dose of sumatriptan (2 mg i. v.) caused no change in rCBF in healthy volunteers (Friberg et al., 1991) . We therefore investigated whether sumatriptan causes pial artery vasocon striction when administered intravenously to anaes thetised cats; the dose selected (6. 4 f.Lg/kg/min i. v. for 10 min) has been previously shown to be effec tive in the acute treatment of migraine (Perrin et al., 1989) . The ability of this dose of sumatriptan to cause an increase in carotid vascular resistance, in dicating carotid vasoconstriction, provided evi dence that in the cat this was a pharmacologically effective dose; the selective vasoconstrictor effect of sumatriptan in the carotid vascular bed of anaes thetised dogs and cats with little or no change in blood pres sure has been described previously. However, de spite causing an increase in carotid vascular resis tance, sumatriptan produced no change in pial ar tery diameter when administered intravenously. Desensitisation of the cerebrovascular smooth mus cle to the effects of sumatriptan had not occurred since perivascular injection of sumatriptan before and after the intravenous infusion caused similar constrictions. This lack of effect of sumatriptan on pial artery diameter when administered intrave nously is in agreement with the lack of effect of sumatriptan on CBF and is most probably explained by the poor ability of sumatriptan to penetrate the cerebrovascular inti mal layer. Thus, intraluminally administered suma triptan would not effectively pass through this bar rier to reach the underlying vascular smooth mus cle. This is in accordance with other studies that show that sumatriptan does not readily penetrate the blood-brain barrier (Humphrey et al., 1990b; Sleight et al., 1990) .
The mechanism of action of sumatriptan in the acute treatment of migraine headache is believed to be attributable to a vasoconstrictor effect on exces sively dilated, pain-sensitive intracranial blood ves sels (Humphrey et al., 1990b; Humphrey, 1991) . Whether its primary site of action is at the level of J Cereb Blood Flow Metab, Vol. 12, No. 3, 1992 the dural or the cerebral vascular bed remains to be determined. However, systemically administered sumatriptan might be expected to gain access more readily to the vascular smooth muscle of dural com pared to cerebral blood vessels because of the lack of tight endothelial cell junctions in the former, The present study suggests that sumatriptan, adminis tered systemically at a clinically relevant dose, does not constrict pial arteries on the brain surface. This is in agreement with a recent transcranial Doppler study that showed that outside of a migraine attack, sumatriptan did not modify the calibre of the middle cerebral artery. However, interestingly, during mi graine, dilation of the middle cerebral artery was found on the headache side only; this was normal ised by sumatriptan without the rCBF being affected (Friberg et al., 1991) , probably due to au toregulatory changes further downstream in the cerebrovascular bed. Thus, it is possible that the vasoconstrictor effect of sumatriptan on the large surface arteries of the brain is more apparent under conditions of dilation and inflammation, as has been suggested to occur during migraine (see the intro duction). The effect of sumatriptan on pial artery diameter under similar conditions would be inter esting to evaluate. Such studies may be of value in further elucidating the mechanism of sumatriptan in aborting migraine headache.
